Drug diversion, which is the transfer of a legally prescribed controlled substance from the individual for whom it was prescribed to another person for illicit use, is a national crisis that affects both public health and social and economic welfare. These activities can harm patients, health care professionals, and the organizations that employ them. It’s important for C suite professionals at health care organizations and CPA business advisers to play an active role in formulating a comprehensive risk and internal audit approach for drug diversion and protection. To discuss these issues, we spoke with Janice Ahlstrom and Kim Wylam of Baker Tilly Virchow Krause LLP. For even more details, check out their informative white paper on the issue.

To read the full transcript click here.